What question did this study set out to answer?

To review the evolution of first- and second-line systemic therapies and highlight emerging post-combination regimens for metastatic clear cell renal cell carcinoma.

April 1, 2023UroOpen Access

Evolving Treatment Options for Metastatic Renal Cell Carcinoma (mRCC)

View Full Paper

Ask AI

Bookmark

To review the evolution of first- and second-line systemic therapies and highlight emerging post-combination regimens for metastatic clear cell renal cell carcinoma.
Synthesized evidence from clinical trials evaluating systemic treatments for metastatic clear cell renal cell carcinoma from 2006 to the present.
Assessed trial data regarding the transition from tyrosine kinase inhibitor monotherapies to contemporary combination regimens and subsequent treatment lines.
Frontline vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI) monotherapy has been replaced by combination regimens, including VEGF-TKIs plus immune checkpoint inhibitors or dual checkpoint blockade with ipilimumab plus nivolumab.
Prior clinical trial findings guiding subsequent-line therapy after TKI monotherapy are no longer directly applicable to patients progressing on contemporary combination treatments.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Narrative review demonstrates shifting therapeutic paradigms in metastatic clear cell renal cell carcinoma, highlighting the rise of combination regimens over monotherapy.

Cite This Study

Yu et al. (2023) studied this question.

synapsesocial.com/papers/6a8a8089176d2ac34cfbe2d3 https://doi.org/10.3390/uro3020014

View Full Paper

Ask AI

Bookmark

Implication

Narrative review demonstrates shifting therapeutic paradigms in metastatic clear cell renal cell carcinoma, highlighting the rise of combination regimens over monotherapy.

Evolving Treatment Options for Metastatic Renal Cell Carcinoma (mRCC)

Key Points

Discussion

Implication

Cite This Study

Evolving Treatment Options for Metastatic Renal Cell Carcinoma (mRCC)

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading